Kristen Spencer, DO, discusses first-line regimen selection in metastatic pancreatic adenocarcinoma.
Personalizing Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer
Kristen Spencer, DO, discusses how patient goals are shaping first-line treatment selection for metastatic pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5